Immunotherapy in advanced gastric cancer, is it the future?

Related Articles

Immunotherapy in advanced gastric cancer, is it the future?

Crit Rev Oncol Hematol. 2019 Jan;133:25-32

Authors: Coutzac C, Pernot S, Chaput N, Zaanan A

Abstract
The prognosis of advanced gastric cancer remains extremely poor despite the use of standard therapies such as chemotherapy and biological agents. Blocking immune checkpoint especially programmed cell death-1 (PD-1) and its ligand (PD-L1 or B7-H1), has proven efficacy in several solid cancers, and seems to become a potential option in gastric cancer treatment. This review will focus on data describing the immune microenvironment of gastric tumors on which blocking PD-1/PD-L1 axis may have an anti-tumor efficacy. Then, the encouraging results of clinical trials evaluating anti-PD-1/PD-L1-based therapeutic strategy in first or later-line settings will be discuss. Finally, clinical outcomes according to PD-L1 expression, mismatch repair phenotype and other potential predictive biomarkers of anti-tumor response will be described. Altogether, immunotherapy seems promising in advanced gastric cancer in monotherapy or in combining strategies probably for a specific subgroup of patients who need to be better identified.

PMID: 30661655 [PubMed - in process]

from A via a.sfakia on Inoreader http://bit.ly/2TeO5yA